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Previewsthey transport bacteria from tissue sites to
initiate bubo formation and, via the pro-
duction of chemokines, recruit mono-
cytes that allow the spread of bacteria to
secondary LNs. However, these two roles
for DCs might not be unique to this cell
type. Monocyte subsets can also traffic
to LNs, raising the possibility that they
could similarly initiate entry from tissues
into dLNs (Jakubzick et al., 2013). The au-
thors’ experiments with an S1P1 inhibitor
argue that internodal trafficking is most
likely the main contribution of monocytes
to disease progression, thus providing a
simple two-cell model of DC-mediated
initial dLN entry followed by monocyte-
mediated secondary LN spread.
The ability to block migration of host
cells, either from the periphery to dLNs
or between LNs, could be an important
therapeutic result. In this study, mice
were treated with FTY720 prior to and
during infection with Y. pestis, and it
would be interesting to see whether
administration following inoculation couldalso block LN egress. Spread to second-
ary LNs occurred within 24 hr postinocu-
lation in the model of St. John et al., so it
remains unclear whether it is feasible to
apply this treatment regimen to prevent
disease progression. It is also unclear
whether host-cell-dependent egress
continued after 24 hr postinoculation
because many bacteria were found extra-
cellularly at later time points. Even so, if
pharmacological inhibitors can block the
spread of the disease within the host,
they could be powerful adjuvants used
in combination with antimicrobials to limit
spread and slow bacterial growth. This
mouse model, utilizing an attenuated
strain that affects the kinetics of disease
progression, will most likely provide a
platform for further experiments to
address the efficacy of therapeutic treat-
ment options.REFERENCES
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In this issue of Immunity, Oh et al. (2014) reveal an unappreciated facet of how the microbiota influences
immune responses. Immunity to nonadjuvanted vaccines depends on Toll-like-receptor-5-mediated sensing
of the microbiota.The distal gut is colonized with an aston-
ishing 1012 bacteria per gram of gut con-
tent. Other body surfaces are also colo-
nized by microbes, which are collectively
referred to as the microbiota. The term
‘‘supraorganism’’ has been coined to
describe the fact that we are ‘‘running fer-
menters,’’ carrying numerically more bac-
teria than we have cells in our body. How-
ever, we are only beginning to understand
the impact of the microbiota on health.
Perhaps not surprisingly, the micro-
biota constantly produce and releasepotent immunostimulatory molecules,
which significantly affect the immune
system. Thus, germ-free animals, i.e.,
animals bred in the absence of any viable
microbes, show substantial differences in
their intestinal mucosal immune system;
such differences include underdeveloped
Peyer’s patches, very few plasma cells,
and reduced numbers of T cells. An
exciting new development comes with
the emerging mechanistic understanding
of the influence of the microbiota on the
host’s immune system. Strikingly, effectsare not restricted to the colonized
mucosal tissue but are also observed
at systemic body sites. For example,
the gut microbiota has been shown to
affect neutrophil maturation in the bone
marrow, susceptibility to type 1 diabetes,
and experimental encephalomyelitis. In
this issue of Immunity, Oh et al. (2014)
show that the gut microbiota can impact
vaccination to flu.
Two seasonally administrated flu
vaccines are available in the USA: a
nonadjuvanted subunit vaccine (trivalentptember 18, 2014 ª2014 Elsevier Inc. 349
Figure 1. Microbiota-Derived Flagellin Acts
as an Adjuvant for Systemic Immunization
Data obtained in experimental mouse models
suggest that microbiota-released flagellin (red dia-
monds) reaches systemic sites and provides, via
TLR5, the costimulus that macrophages and B
cells (green) need to induce antibodies to exoge-
nously administered adjuvant-free TIV influenza
vaccine antigen (blue triangles). The critical role
of the microbiota-derived flagellin suggests that
microbiota alterations might influence the efficacy
of adjuvant-free vaccination strategies.
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Previewsinactivated vaccine, or TIV) and a live
attenuated influenza strain. Despite the
effectiveness of TIV, it has remained un-
clear how the vaccine can elicit protective
immunity in the absence of an adjuvant or
infection. Adjuvants or complete infective
microorganisms contain innate immune
stimuli and provide the costimulus
required for efficient activation of the
adaptive immune system. Oh et al. now
show that TIV responses are reduced
in Toll-like receptor 5 (TLR5)-deficient
mice, which are unable to respond to the
bacterial innate immune stimulus flagellin,
as well as in germ-free mice or mice that
have undergone sustained treatment
with antibiotics. Colonization of germ-
free mice with flagellin-expressing but
not flagellin-mutated bacteria was able
to revert the phenotype. Oh et al. suggest
that this effect is mediated by TLR5
expression on immune cells such as B
cells and macrophages at systemic sites.
It therefore appears that bacterial flagellin
derived from the microbiota reaches im-
mune cells at systemic sites and provides
the costimulus and adjuvant for the TIV
vaccine (Figure 1).350 Immunity 41, September 18, 2014 ª2014Several members of the mammalian
microbiota express flagella, and the
structural subunit flagellin is constantly
released. But howdoes flagellin produced
in the gut lumen reach systemic sites?
Although flagellin is as potent as lipopoly-
saccharide (LPS) for driving immunoglob-
ulin synthesis in B cells in vitro, Oh et al.
demonstrate that the absence of TLR5 is
sufficient to impair the vaccine response.
Many years ago, flagellin (at the time
called proinflammatory factor, PIF) was
shown to rapidly cross the polarized
intestinal epithelium and concentrate at
the basolateral site (Gewirtz et al., 2001).
This is in contrast to LPS, which forms
a steep gradient between gut lumen
and the epithelial surface (Dupont et al.,
2014). Nevertheless, several microbial
stimuli reach the subepithelial tissue.
Gut-derived TLR4 and TLR9 ligands,
LPS and bacterial DNA, respectively,
were shown to reach the liver via the por-
tal vein and drive nonalcoholic fatty liver
disease (NAFLD) in mice (Henao-Mejia
et al., 2012). Although the liver efficiently
removes exogenous molecules, some
might evade this process and reach
systemic sites. Indeed, gut-microbiota-
derived peptidoglycan fragments can
reach the bone marrow. However, the
systemic spread of gut-derived flagellin
has not been examined.
Previous work suggested a differential
effect of the skin and gut microbiota
on skin- and gut-draining lymph nodes,
respectively (Naik et al., 2012). In
contrast, the work by Oh et al. suggests
a direct effect of the gut microbiota on
the differentiation or survival of plasma
cells in the peripheral lymph nodes.
Thus, depending on their precise
anatomical location, lymph nodes might
be affected by microbial products com-
ing from different sources, including their
respective draining region and the gut.
Macrophages might be particularly
suited to capture microbial products
and thereby set the tone for on-going im-
mune responses. As an alternative to
direct spread, phagocytic cells might
internalize microbiota constituents at
the mucosal surface and transport them
to systemic sites. Interestingly, in the
gut lamina propria a myeloid TLR5-ex-
pressing cell population has been
described as regulating IgA-secreting
plasma cells (Uematsu et al., 2008).
Medullary macrophages situated in closeElsevier Inc.proximity to recently generated plasma
cells might perform a similar function in
peripheral lymph nodes.
The observations made by Oh et al.
suggest that antibiotic treatment and in-
testinal dysbiosis might affect vaccina-
tion in humans. However, the degree
of microbiota alteration in the chosen
models most probably exceeds the
effects of standard antibiotic regi-
mens. Numerous gut-inhabiting bacteria,
including members of the phylum Proteo-
bacteria, can produce flagellae; others,
such as the common commensal bacte-
rium Bacteroides fragilis, lack synthesis
and motility (Lozupone et al., 2012). Mi-
crobiota alterations might thus influence
the luminal flagellin concentration and
thereby alter the threshold of immune
activation, including that at systemic
sites. The stimulatory potential of
different flagellin molecules produced dif-
fers substantially; for example, Campylo-
bacter spp. or Helicobacter spp. (both
ε-proteobacteria) produce only weakly
stimulatory flagellin, whereas the g-pro-
teobacteria Escherichia coli and Salmo-
nella enterica produce highly potent
flagellin (Andersen-Nissen et al., 2005).
Antibiotics modulating the abundance of
species producing stimulatory flagellin
along with changes in overall colonization
levels and integrity of the gut barrier
could potentially affect the availability of
TLR5 ligands in the periphery. Moreover,
composition and density of the micro-
biota is regulated at various levels by
innate and adaptive immune responses.
TLR5-deficient mice exhibit a signifi-
cantly altered microbiota (Vijay-Kumar
et al., 2010). Also, changes in flagella-
related gene expression, elevated
amounts of flagellin in the gut, and flagel-
lated bacteria penetrating intestinal villi
have been described in TLR5-deficient
mice (Cullender et al., 2013). Thus, the ef-
fect of TLR5 deficiency might be more
complex and at least in some aspects
go beyond the effect of antibiotic treat-
ment. Antibiotics differentially affecting
distinct bacterial groups showed compa-
rable effects of TIV antibody responses.
This further emphasizes the idea that
vaccination efficacy might not rely on
distinct bacterial species exclusively but
rather also on overall colonization levels,
integrity of the gut barrier, and functional
levels of microbial products in the
periphery.
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PreviewsInterestingly, the effect of antibiotic
treatment was limited to two nonadju-
vated vaccines, TIV and another viral
subunit vaccine to polio. In contrast, im-
munization with alum-absorbed toxoids,
the HIVenv protein as well as a live-atten-
uated yellow fever vaccine, were unaf-
fected. Thus, the microbiota has no
detectable effect on the induced humoral
response to adjuvanted vaccines or
attenuated pathogens. Flagellin has long
been known to represent a potent immu-
nostimulatory molecule and useful adju-
vant. The presented data now reveal an
unexpected role of naturally produced
flagellin derived from the microbiota to
provide costimulation for immune activa-
tion. Thus, the intestinal microbiota might
effectively take the function of a natural
adjuvant. This view is consistent with les-
sons learned from gut immunology: the
microbiota is an essential driver of ho-meostasis and a key part of an effective
immune system.REFERENCES
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Proinflammatory macrophage activation is coupled to a metabolic switch toward glycolysis. In Cell Meta-
bolism, Jin et al. (2014) show that this process is negatively regulated by mitochondrial electron transport
chain complex I through both cell intrinsic and extrinsic pathways.There is a link between anti-inflammatory
properties and mitochondrial oxidative
phosphorylationontheonehand,andclas-
sical activation and glycolytic metabolism
on the other (O’Neill and Hardie, 2013). In
their recent paper in Cell Metabolism, Jin
and colleagues highlight the importance
of complex I (CI) in regulating macrophage
activation by showing that deletion of the
CI component Ndufs4 causes a switch in
the metabolic balance toward glycolysis
and associated changes in the monocyte,
macrophage, and osteoclast lineage that
result in the development of inflammatory
disease symptoms and abnormal bone
density (Jin et al., 2014).
The electron transport chain (ETC),
which links nutrient oxidation to ATPproduction by oxidative phosphorylation
(OXPHOS), consists of complexes I–V
in the mitochondrial inner membrane
(Figure 1). CI is composed of >45 sub-
units and is highly regulated by path-
ways initiated by various extracellular
signals (Papa et al., 2012). Unsurpris-
ingly, mutations in genes encoding com-
ponents of CI are associated with severe
clinical disease (Papa et al., 2012). From
an immunologic perspective, CI is inter-
esting not only because of its core func-
tion in metabolism but because along
with complex III, it is a site of reactive
oxygen species (ROS) production (Sena
and Chandel, 2012). ROS plays a role
in a range of innate cell functions, and
indeed Toll-like receptor (TLR) signalinghas been linked to increased production
of mitochondrial ROS for bacterial killing
(Sena and Chandel, 2012). However,
ROS can be detrimental when produced
in excess, and this can occur when CI
function is compromised (Chen et al.,
2007).
Ndufs4/ mice have been used to
model CI deficiency and have been found
to die from encephalomyopathy approxi-
mately 7 weeks after birth (Kruse et al.,
2008). Using these mice, Jin and col-
leagues discovered that by 3 weeks
after birth, the absence of Ndufs4 led
to systemic inflammation, apparent as
increased levels of proinflammatory cyto-
kines, systemically increased numbers of
Ly6chi monocytes and the developmentptember 18, 2014 ª2014 Elsevier Inc. 351
